1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. News
  7. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-12 am EDT
168.95 CHF   +0.24%
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/10Australia's CSL Closes Vifor Pharma Purchase
MT
08/10CSL Completes Vifor Pharma Acquisition
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

VAT To Replace Vifor Pharma On Swiss Leader Index

03/24/2022 | 03:43am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BACHEM HOLDING AG 2.75% 69.15 Delayed Quote.-53.00%
MEYER BURGER TECHNOLOGY AG -1.80% 0.572 Delayed Quote.43.12%
SENSIRION HOLDING AG 1.91% 117.4 Delayed Quote.-13.64%
VAT GROUP AG -2.64% 265.8 Delayed Quote.-39.92%
VIFOR PHARMA AG 0.24% 168.95 Delayed Quote.3.88%
All news about VIFOR PHARMA AG
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/10Australia's CSL Closes Vifor Pharma Purchase
MT
08/10CSL Completes Vifor Pharma Acquisition
MT
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P Global BMI Index
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology &..
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350 - Health Care
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P Global 1200
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P International 700
CI
08/05VIFOR PHARMA AG(SWX : VIFNE) dropped from FTSE All-World Index
CI
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Financials
Sales 2022 2 005 M 2 125 M 2 125 M
Net income 2022 346 M 366 M 366 M
Net cash 2022 645 M 683 M 683 M
P/E ratio 2022 40,4x
Yield 2022 1,28%
Capitalization 10 963 M 11 624 M 11 624 M
EV / Sales 2022 5,15x
EV / Sales 2023 4,51x
Nbr of Employees 2 200
Free-Float 99,8%
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 168,95 CHF
Average target price 163,25 CHF
Spread / Average Target -3,37%
EPS Revisions
Managers and Directors
Shah Abbas Hussain Chief Executive Officer
Alexandros Sigalas Chief Financial Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Frédéric Zwahlen Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VIFOR PHARMA AG3.88%11 631
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211